Cubilin Renal Receptor and Related Renal Failure Therapeutics
Technology description
Researchers led by Dr. Timothy Hammond at Tulane University and Dr. Pierre Verroust in France have identified cubilin, a major renal receptor protein that mediates the toxicity of a number of small ligands by cell uptake. The multiligand cubilin receptor is massively expressed in the proximal convoluted tubule. Cubilin is a 460 kd protein containing 13%-14% carbohydrates and is composed of a large repeating array of ligand binding CUB (complement C1r/C1s, UEGF, and Bone morphogenic protein-1) domains. A list of cubilin-binding ligands includes hemoglobin-based artificial blood products, polybasic drugs such as amnioglycoside antibiotics, myeloma light chains, albumin, transferrin, and apolipoprotein A-I.
Application area
The development of cubilin-based therapeutic agents to prevent or manage renal toxicity in patients treated with artificial blood or aminoglycoside antibiotics.
Advantages
ΓÇó Development of therapeutic agents to prevent renal toxicity from hemoglobin-based artificial blood products and aminoglycoside antibiotics ΓÇó Development of therapeutic agents to remove heavy metals from the body ΓÇó Development of therapeutic agents for the treatment/prevention of acute renal failure
May 20, 2013
B5, No.1600, North Guoquan Rd, Yangpu, Shanghai
info@yintrust.com
021-65679356
Premium